Skip to main content

Table 3 Baseline parameters showing annual costs and utility values associated with BPH treatment

From: A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

Annual cost associated with treatment

 
 

Dutasteride US$

Fixed dose therapy US$

 

Moderate BPH

 

338.82

Cost generated from cost data in two regional tertiary health centres in Nigeria

Severe BPH

223.53

338.82

TURP

484.97

484.97

AUR

29.41

29.41